Aimmune Therapeutics Inc (NASDAQ:AIMT) insider Mary M. Rozenman sold 6,592 shares of the stock in a transaction on Thursday, February 1st. The shares were sold at an average price of $35.36, for a total value of $233,093.12. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.
Shares of Aimmune Therapeutics Inc (NASDAQ AIMT) traded down $0.86 during trading hours on Monday, reaching $35.32. The company’s stock had a trading volume of 366,114 shares, compared to its average volume of 410,338. The stock has a market capitalization of $1,800.00 and a PE ratio of -15.09. Aimmune Therapeutics Inc has a fifty-two week low of $15.97 and a fifty-two week high of $40.65.
Aimmune Therapeutics (NASDAQ:AIMT) last announced its earnings results on Monday, November 6th. The biotechnology company reported ($0.63) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.72) by $0.09. equities analysts expect that Aimmune Therapeutics Inc will post -2.51 earnings per share for the current year.
Several research analysts have issued reports on AIMT shares. Zacks Investment Research raised Aimmune Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday, October 16th. Piper Jaffray Companies set a $38.00 target price on Aimmune Therapeutics and gave the stock a “buy” rating in a research report on Saturday, October 21st. Wedbush reissued an “outperform” rating and issued a $70.00 target price (up from $42.00) on shares of Aimmune Therapeutics in a research report on Monday, October 23rd. Credit Suisse Group raised their target price on Aimmune Therapeutics from $36.00 to $45.00 and gave the stock an “outperform” rating in a research report on Monday, October 23rd. Finally, Roth Capital started coverage on Aimmune Therapeutics in a research report on Monday, November 20th. They issued a “buy” rating and a $60.00 target price on the stock. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and six have given a buy rating to the company’s stock. Aimmune Therapeutics currently has an average rating of “Hold” and an average price target of $57.57.
COPYRIGHT VIOLATION WARNING: This report was originally published by American Banking News and is the property of of American Banking News. If you are reading this report on another site, it was illegally copied and republished in violation of international copyright and trademark legislation. The correct version of this report can be read at https://www.americanbankingnews.com/2018/02/05/aimmune-therapeutics-inc-aimt-insider-sells-233093-12-in-stock.html.
About Aimmune Therapeutics
Aimmune Therapeutics, Inc is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company’s therapeutic approach, which it refers to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services.
Receive News & Ratings for Aimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.